Skip to main content

Advertisement

SpringerLink
Log in

Central nervous system neuroblastoma metastases pseudoprogression following intraventricular anti-B7-H3 radioimmunotherapy

  • Letter to the Editor
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Flem-Karlsen K, Fodstad O, Tan M, Nunes-Xavier CE (2018) B7–H3 in cancer—beyond immune regulation. Trends Cancer 4:401–404. https://doi.org/10.1016/j.trecan.2018.03.010

    Article  CAS  PubMed  Google Scholar 

  2. Yu TT, Zhang T, Lu X, Wang RZ (2018) B7–H3 promotes metastasis, proliferation, and epithelial-mesenchymal transition in lung adenocarcinoma. Onco Targets Ther 11:4693–4700. https://doi.org/10.2147/OTT.S169811

    Article  PubMed  PubMed Central  Google Scholar 

  3. Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, Takahama T, Tanaka K, Hayashi H, Takeda M, Kato S, Maenishi O, Sakai K, Chiba Y, Okabe T, Kudo K, Hasegawa Y, Kaneda H, Yamato M, Hirotani K, Miyazawa M, Nishio K, Nakagawa K (2018) B7–H3 negatively modulates CTL-mediated cancer immunity. Clin Cancer Res 24:2653–2664. https://doi.org/10.1158/1078-0432.CCR-17-2852

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to thank Joseph Olechnowicz for editorial assistance. The authors acknowledge the NCI Cancer Center Support Grant P30 CA008748.

Author information

Authors and Affiliations

  1. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 429, New York, NY, 10065, USA

    Kim Kramer

  2. University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

    Osman Khan

  3. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA

    Sofia Haque

Authors
  1. Kim Kramer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Osman Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sofia Haque
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kim Kramer.

Ethics declarations

Conflict of interest

MSK has partnered with Y-mAbs Therapeutics to develop Omburtamab and has a financial contract with Y-mAbs Therapeutics. Dr. Kim Kramer is a consultant to Y-mAbs Therapeutics, Inc. Omburtamab was licensed to Y-mAbs Therapeutics in 2015. The clinical trial discussed was not sponsored by Y-mAbs Therapeutics.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kramer, K., Khan, O. & Haque, S. Central nervous system neuroblastoma metastases pseudoprogression following intraventricular anti-B7-H3 radioimmunotherapy. J Neurooncol 144, 227–229 (2019). https://doi.org/10.1007/s11060-019-03203-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-019-03203-1

Search

Navigation